×
About 6,231 results

ALLMedicine™ Schizoaffective Disorder Center

Research & Reviews  2,941 results

The clinical relevance of gray matter atrophy and microstructural brain changes across ...
https://doi.org/10.1016/j.schres.2021.01.016
Schizophrenia Research; Hanlon FM, Dodd AB et. al.

Feb 19th, 2021 - Patients with psychotic spectrum disorders (PSD) exhibit similar patterns of atrophy and microstructural changes that may be associated with common symptomatology (e.g., symptom burden and/or cognitive impairment). Gray matter concentration values...

Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia: Prevalence...
https://doi.org/10.1097/JCP.0000000000001357
Journal of Clinical Psychopharmacology; de Beaurepaire R

Feb 15th, 2021 - Excessive energy intake likely favors metabolic dysfunction in patients with schizophrenia and may be, in part, the consequence of antipsychotic treatments. However, previous studies on the prevalence of bulimia and binge eating symptoms in antips...

Using the MMSE-2 to Measure Cognitive Deterioration in a Sample of Psychiatric Patients...
https://doi.org/10.3390/ijerph18041694
International Journal of Environmental Research and Publi... Ralat SI

Feb 13th, 2021 - Patients with psychiatric disorders often have cognitive impairment. Several deficits have been recognized in patients with mood and/or psychotic disorders. We hypothesized that differences in the levels of deterioration exist between patients wit...

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder.
https://doi.org/10.1093/schbul/sbab004
Schizophrenia Bulletin; Lintunen J, Taipale H et. al.

Feb 3rd, 2021 - To investigate the long-term real-world effectiveness of antipsychotics and other psychopharmacotherapies in the treatment of schizoaffective disorder (SCHAFF). Two nationwide cohorts of SCHAFF patients were identified from Finnish and Swedish reg...

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in peop...
https://doi.org/10.1111/dom.14334
Diabetes, Obesity & Metabolism; Whicher CA, Price HC et. al.

Feb 2nd, 2021 - To investigate the feasibility and acceptability of using liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis. A double-blind, randomized, placebo-...

see more →

Drugs  87 results see all →

Clinicaltrials.gov  3,099 results

The clinical relevance of gray matter atrophy and microstructural brain changes across ...
https://doi.org/10.1016/j.schres.2021.01.016
Schizophrenia Research; Hanlon FM, Dodd AB et. al.

Feb 19th, 2021 - Patients with psychotic spectrum disorders (PSD) exhibit similar patterns of atrophy and microstructural changes that may be associated with common symptomatology (e.g., symptom burden and/or cognitive impairment). Gray matter concentration values...

Clozapine - clozapine tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c5b637d-bc69-4b27-abca-5e82077a7fd0

Feb 17th, 2021 - Clozapine tablets are an atypical antipsychotic indicated for: •Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. (1.1, 14.1) •Reducing suicidal behavior in patients with schizophrenia or schizoaffective di...

Clozapine - clozapine tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d76f0fa7-467d-4c24-acca-c884d5a7f1f0

Feb 17th, 2021 - Clozapine tablets are an atypical antipsychotic indicated for: •Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. (1.1, 14.1) •Reducing suicidal behavior in patients with schizophrenia or schizoaffective di...

Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia: Prevalence...
https://doi.org/10.1097/JCP.0000000000001357
Journal of Clinical Psychopharmacology; de Beaurepaire R

Feb 15th, 2021 - Excessive energy intake likely favors metabolic dysfunction in patients with schizophrenia and may be, in part, the consequence of antipsychotic treatments. However, previous studies on the prevalence of bulimia and binge eating symptoms in antips...

Using the MMSE-2 to Measure Cognitive Deterioration in a Sample of Psychiatric Patients...
https://doi.org/10.3390/ijerph18041694
International Journal of Environmental Research and Publi... Ralat SI

Feb 13th, 2021 - Patients with psychiatric disorders often have cognitive impairment. Several deficits have been recognized in patients with mood and/or psychotic disorders. We hypothesized that differences in the levels of deterioration exist between patients wit...

see more →

News  99 results

Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis
https://reference.medscape.com/viewarticle/923959_1

Feb 20th, 2020 - Tardive dyskinesia (TD) is a troubling side effect that may occur with long-term dopaminergic antagonist medications. TD manifests as involuntary movements of the tongue, lips, face, trunk, and extremities. It is most commonly seen in patients wit...

Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis
https://reference.medscape.com/viewarticle/923959

Feb 20th, 2020 - Tardive dyskinesia (TD) is a troubling side effect that may occur with long-term dopaminergic antagonist medications. TD manifests as involuntary movements of the tongue, lips, face, trunk, and extremities. It is most commonly seen in patients wit...

Perceived Barriers and Facilitators of Clozapine Use: A National Survey of Veterans Affairs Prescribers
https://www.mdedge.com/fedprac/article/209881/mental-health/perceived-barriers-and-facilitators-clozapine-use-national?channel=112
Breanna L. Moody, PharmD, Courtney V. Eatmon, PharmD, BCPP

Oct 10th, 2019 - Clozapine is an atypical antipsychotic that the US Food and Drug Administration (FDA) approved for use in schizophrenia and suicidality associated with schizophrenia or schizoaffective disorder. Clozapine has been shown to be superior to other ant.

Consider patients’ perceptions of tardive dyskinesia
https://www.mdedge.com/psychiatry/article/202113/schizophrenia-other-psychotic-disorders/consider-patients-perceptions?channel=53
Gina L. Henderson

Jun 3rd, 2019 - SAN FRANCISCO – Assessing the impact of tardive dyskinesia on the lives of patients requires more than just visual observation, Stanley N. Caroff, MD, said at the annual meeting of the American Psychiatric Association.

Fast Five Quiz: How Much Do You Know About Tardive Dyskinesia?
https://reference.medscape.com/viewarticle/910550

Apr 29th, 2019 - Tardive dyskinesia (TD) is a movement disorder caused by the long-term use of dopaminergic antagonists or other antipsychotic medications. Patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have a history of long-term u...

see more →

Patient Education  5 results see all →